CSF3 and neutropenia: Furthermore, our results demonstrated that single-agent vinorelbine administered three times a week was well tolerated and only 4% of the patients experienced grade 3 adverse reactions (neutropenia), thereby requiring granulocyte colony-stimulating factor administration.